"目录号: HY-14800
Anti-infection-
Radezolid 是一种恶唑烷酮类抗生素。
Bacterial
相关产品
G-418 disulfate-Anisomycin-Salinomycin-Avibactam sodium-Vancomycin hydrochloride-Hygromycin B-Bleomycin sulfate-Ciprofloxacin-Minocycline hydrochloride-Ampicillin sodium-Tetracycline hydrochloride-Tebipenem-Kanamycin sulfate-Solithromycin-Tedizolid-
生物活性
Description
Radezolid is a novel oxazolidinone antibiotic agent.
In Vitro
Radezolid MICs are systematically equal to or lower (up to 3 log2 dilutions) than those of linezolid for all linezolid-susceptible strains, with an 8-fold difference for the linezolid-resistant strains. Radezolid shows a greater potency than linezolid, independent of the bacteria tested, when concentrations are expressed on a weight (mg/L) basis. Radezolid shows an improved potency compared to that of linezolid when concentrations are expressed on a weight (mg/L) basis[1]. Radezolid and TR-700 perform well against 3-copy G2447T, G2576T, and G2576T/T2571C mutants[2].
Clinical Trial
NCT00640926
Melinta Therapeutics, Inc.
Community-Acquired Pneumonia (CAP)
October 2007
Phase 2
NCT00646958
Melinta Therapeutics, Inc.
Infectious Skin Diseases-Bacterial Skin Diseases-Staphylococcal Skin Infections-Streptococcal Infections-Abscess
December 2007
Phase 2
View MoreCollapse
References
[1].Lemaire S, et al. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila.
[2].Locke JB, et al. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob Agents Chemother. 2010 Dec;54(12):5337-43.